ArticleCureus2026
Prevalence and Impact of Chronic Liver Disease in Adult Patients Admitted With Cystic Fibrosis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCystic fibrosis (CF) is a genetic, multisystem disorder characterized by progressive lung disease driven by mucus obstruction, chronic inflammation, and recurrent infections. Although chronic liver disease (CLD) is a recognized complication of CF, its prevalence and clinical impact among hospitalized adults with CF have not been well characterized using large-scale national databases.
methodsWe utilized the National Inpatient Sample (NIS) database to identify adults aged ≥18 years hospitalized between 2015 and 2019 with a diagnosis of CF. Patients were stratified based on the presence or absence of CLD. International Classification of Diseases (ICD) codes were used to identify comorbidities, including congestive heart failure, prior myocardial infarction, atrial fibrillation, obesity, chronic kidney disease, and end-stage renal disease. Multivariable regression analyses were performed to evaluate in-hospital mortality, length of stay, hospital costs, and in-hospital complications, including sepsis, pneumonia, acute kidney injury (AKI), and the need for intubation, tracheostomy, and gastrostomy.
resultsAmong an estimated 90,675 hospitalized adults with CF, 11.68% had concomitant CLD. In multivariable analyses, patients with CLD had significantly higher in-hospital mortality compared with those without CLD (2.50% vs. 1.24%, P<0.001). The CLD group also experienced longer hospital stays (10.4 vs. 8.6 days, P<0.001) and higher hospitalization costs ($38,880 vs. $31,246, P=0.019). The coexistence of CF and CLD was associated with a significantly increased risk of in-hospital complications, including sepsis (6.47% vs. 4.20%, P<0.001), AKI (17.13% vs. 11.79%, P<0.001), and malnutrition (42.63% vs. 31.49%, P=0.002). There were no significant differences between groups in the rates of pneumonia (21.00% vs. 20.57%, P=0.596), need for intubation (2.74% vs. 1.92%, P=0.139), tracheostomy (0.69% vs. 0.54%, P=0.072), or gastrostomy (0.89% vs. 0.66%, P=0.499).
conclusionsCLD is common among adults hospitalized with CF and is independently associated with higher in-hospital mortality, longer length of stay, and increased hospital costs. Additionally, CLD confers a significantly higher risk of sepsis, AKI, and malnutrition. These findings underscore the importance of early recognition and proactive management of liver disease in hospitalized patients with CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.